Compare Johnson & Johnson (JNJ) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Northrop Grumman Corporation — how do they compare? Johnson & Johnson trades at $249.4 (market cap $598.96B), while Northrop Grumman Corporation trades at $512.22 (market cap $74.42B). The key difference: Johnson & Johnson is far larger — about 8× Northrop Grumman Corporation's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | NOC | |
|---|---|---|
Market Cap | $598.96B | $74.42B |
Volume | 6,156,228 | — |
Sector | Health | Industrials |
52-Week High | $267.24 | $768.02 |
52-Week Low | $164.36 | $496.02 |
Enterprise Value | $631.90B | $88.65B |
Dividend Yield | 2.15% | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Northrop Grumman (NOC) trades at $524.14, up 0.49% with a bearish technical signal despite strong fundamentals. The company shows consistent earnings beats, with Q1 2026 EPS of $6.14 exceeding expectations of $6.06. Recent news highlights defense budget optimism and a $312.3M Navy contract for electronic warfare systems. Technical indicators show RSI at oversold levels near support at $518, while moving averages signal bearish momentum.
The investment outlook remains positive with analyst consensus at Buy (57% of 35 analysts) and a $655 price target representing 25% upside. Risks include execution challenges in defense programs and potential margin pressure. Strong cash flow generation and a $96B backlog support long-term growth, though near-term technical weakness may present entry opportunities for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
